Submit Content
Get the latest delivered to your inbox
Privacy Policy

Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.

 

Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.

    Leprosy on the Brink of Elimination: Public Health Leaders Prepare for Final Push Image

    POSTED 

    01-24-08

    Leprosy on the Brink of Elimination: Public Health Leaders Prepare for Final Push

    BASEL - January 24, 2008 - World Leprosy Day 2008, on Sunday January 27, heralds a historic moment: leprosy is on the brink of elimination after more than two thousand years as a disabling disease that cruelly isolated and impoverished the people it infected. Healthcare lea...

    Experts Debate "Making Aid Work" for the Developing World at Annual Novartis Foundation for Sustainable Development Symposium Image

    POSTED 

    12-07-07

    Experts Debate "Making Aid Work" for the Developing World at Annual Novartis Foundation for Sustainable Development Symposium

  • Growing public debate on development cooperation and pressure to produce measurable results
  • "Performance-based funding," which is increasingly being accepted, offers a potential solution for more efficient aid activiti...
  • Novartis Awards Program Drives Energy Savings and Environmental Progress Image

    POSTED 

    12-05-07

    Novartis Awards Program Drives Energy Savings and Environmental Progress

  • The 2007 Novartis Energy Excellence Awards honor sites in Italy, the UK and US
  • Awards program, in its fourth year, recognizes contributions by Novartis associates to conserving energy and reducing emissions for t...
  • Over 10,000 Novartis Associates Worldwide Take Part in Community Partnership Day Image

    POSTED 

    04-26-07

    Over 10,000 Novartis Associates Worldwide Take Part in Community Partnership Day

    • Novartis organizes annual Community Partnership Day to commemorate the company’s creation in 1996

  • Over 10 000 associates worldwide engage in volunteer activities in their communities
  • Novartis Delivers 4.7 Million Treatments of Anti-malarial Medicine to Tanzania on Africa Malaria Day Image

    POSTED 

    04-25-07

    Novartis Delivers 4.7 Million Treatments of Anti-malarial Medicine to Tanzania on Africa Malaria Day

    • Malaria is leading cause of death in children and adults in Tanzania

    • Novartis reinforces commitment to deliver its anti-malarial, Coartem®, without profit, to patients living in malaria-endemic countries
    Novartis Foundation Partners with Tanzanian Government With Innovative Public Awareness Campaign to Fight Spread of Tuberculosis Image

    POSTED 

    03-22-07

    Novartis Foundation Partners with Tanzanian Government With Innovative Public Awareness Campaign to Fight Spread of Tuberculosis

    - Tuberculosis, striking about 1 in 10 people worldwide, still a growing threat in Africa

    Basel, March 23, 2007 "“ Treatments for disease commonly take the form of pills, but the treatment for tuberculosis begins with a message: TB is cur...

    Novartis Institute for Tropical Diseases Inaugurates New Indonesian Research Initiative to Study Dengue fever, Tuberculosis and Malaria Image

    POSTED 

    01-25-07

    Novartis Institute for Tropical Diseases Inaugurates New Indonesian Research Initiative to Study Dengue fever, Tuberculosis and Malaria

  • NITD partnership with the Eijkman Institute and Hasanuddin University to expand the Singapore-based research institute’s capabilities and expertise
  • Focus on developing novel research approaches for some of the world’s m...
  • 'Development Cooperation at a Crossroads: Dead End or New Horizons?' - 8th Annual Symposium of the Novartis Foundation for Sustainable Development Image

    POSTED 

    12-08-06

    'Development Cooperation at a Crossroads: Dead End or New Horizons?' - 8th Annual Symposium of the Novartis Foundation for Sustainable Development

    BASEL, December 8, 2006 - At the 8th annual symposium of the Novartis Foundation for Sustainable Development, international experts discussed the role of development cooperation in today's and tomorrow's world. While the morning was devoted to a critical assessment of...

    Novartis Spearheads Innovative Malaria Research Project In Newly Created Public-Private Partnership Image

    POSTED 

    05-23-06

    Novartis Spearheads Innovative Malaria Research Project In Newly Created Public-Private Partnership

    Basel - Dr. Daniel Vasella, Chairman and CEO of Novartis, announced today that the Novartis Institute for Tropical Diseases (NITD) will initiate research on malaria - estimated to annually kill more than one million people worldwide and one of the top three killer dis...

    Novartis Accelerates Production of Life-Saving Malaria Treatment Coartem® Image

    POSTED 

    01-18-06

    Novartis Accelerates Production of Life-Saving Malaria Treatment Coartem®

    Basel, Switzerland--Novartis announced today that it is on track to produce 100 million treatment courses of its anti-malarial Coartem (artemether/lumefantrine) in 2006 (up from 30 million in 2005), if orders are placed by malaria-endemic developing countries in a tim...

    Novartis Logo

    Novartis

    Novartis

    Join today and get the latest delivered to your inbox